Qu Biologics

Qu Biologics

March 24, 2015 10:00 ET

Qu Biologics Begins Research Collaboration with the University of Rochester, New York

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 24, 2014) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today it has initiated a research collaboration with the laboratory of Dr. Michael R. Elliott of the University of Rochester School of Medicine and Dentistry.

Dr. Elliott's lab is testing the capacity of Qu Biologics' SSIs to activate macrophages for enhanced activity in vivo using novel preclinical mouse models and state-of-the-art immunologic assays systems. Dr. Elliott is a recognized expert in macrophage biology and function, having published in Nature, the Journal of Cell Biology and the Journal of Immunology. Dr. Elliott's lab is part of the David H. Smith Center for Vaccine Biology and Immunology at the University of Rochester in upstate New York. Dr. Elliott has developed advanced mouse models to assess macrophage activation and efficacy in vivo.

Qu Biologics' Chief Scientific Officer Dr. David Mullins commented, "Qu is pleased to be working with the University of Rochester to evaluate the effects of our proprietary SSIs in Dr. Elliott's highly-informative and unique mouse model system." Dr. Mullins added, "Qu has demonstrated that SSIs induce effective immune responses in preclinical models of cancer and inflammatory bowel disease, and Dr. Elliott's work will advance our detailed understanding of the role of a specific cell - the macrophage - in SSIs' biologic activity."

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body's normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases, such as inflammatory bowel disease. The company is currently recruiting participants for a placebo-controlled, randomized clinical trial in Crohn's disease and a clinical trial in non-small cell lung cancer, and is initiating a trial in ulcerative colitis in Q2 2015.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com.

Qu Biologics Inc. cautions you that statements included in this release that are not a description of historical facts may contain forward-looking statements. These forward-looking statements are only predictions and may involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Contact Information